INNOVIVA, INC. Increase (Decrease) in Other Operating Liabilities
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Other Operating Liabilities of -$128.00 thousand for the 12-month period ending 2010-12-31, per its 10-K filed 2013-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2013-02-26
- INNOVIVA, INC. increase (decrease) in other operating liabilities for the quarter ending 2010-12-31 was $261.00K.
- INNOVIVA, INC. increase (decrease) in other operating liabilities for the quarter ending 2010-09-30 was $0.00.
- INNOVIVA, INC. increase (decrease) in other operating liabilities for fiscal 2010 was -$128.00K, a 132.90% decline from fiscal 2009.
- INNOVIVA, INC. increase (decrease) in other operating liabilities for fiscal 2009 was $389.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2010-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $261.00K derived: sum of 2 quarters · filed 2013-02-26 | -$128.00K 10-K · filed 2013-02-26 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | -$389.00K 10-Q · filed 2011-11-02 | ||
| 2010-06-30 | -$389.00K 10-Q · filed 2011-08-03 | |||
| 2009-12-31 | $389.00K 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |